Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.

MLA

Stemmer, Salomon M., et al. “Clinical Outcomes in ER+ HER2 -Node-Positive Breast Cancer Patients Who Were Treated According to the Recurrence Score Results: Evidence from a Large Prospectively Designed Registry.” NPJ Breast Cancer, vol. 3, Sept. 2017, p. 32. EBSCOhost, https://doi.org/10.1038/s41523-017-0033-7.

APA

Stemmer, S. M., Steiner, M., Rizel, S., Geffen, D. B., Nisenbaum, B., Peretz, T., Soussan-Gutman, L., Bareket-Samish, A., Isaacs, K., Rosengarten, O., Fried, G., McCullough, D., Svedman, C., Shak, S., Liebermann, N., & Ben-Baruch, N. (2017). Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry. NPJ Breast Cancer, 3, 32. https://doi.org/10.1038/s41523-017-0033-7

Chicago

Stemmer, Salomon M, Mariana Steiner, Shulamith Rizel, David B Geffen, Bella Nisenbaum, Tamar Peretz, Lior Soussan-Gutman, et al. 2017. “Clinical Outcomes in ER+ HER2 -Node-Positive Breast Cancer Patients Who Were Treated According to the Recurrence Score Results: Evidence from a Large Prospectively Designed Registry.” NPJ Breast Cancer 3 (September): 32. doi:10.1038/s41523-017-0033-7.